Perfadex Plus
Xvivo Perfusion AB · Decision date Jul 23, 2026
What did the FDA decide?
FDA records K261644 as a 510(k) premarket notification, with a decision dated Jul 23, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jul 23, 2026
Regulatory record facts
- Identifier
- K261644
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Xvivo Perfusion AB
- Product code
- KDN
- Decision code
- SESE
- Decision date
- Jul 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Perfusion, Kidney.
- Applicant
- Xvivo Perfusion AB
- Product code
- KDN
- FDA device class
- 2
FDA decision timeline
K261644 received
Application receipt date recorded by FDA.
K261644 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KDN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | 510(k) clearance | Jun 1, 2026 | FDA | |
| Paragonix Technologies Inc. | 510(k) clearance | Jan 30, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Xvivo Perfusion AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Mölndal
Sources and methodology
- Original FDA record: K261644
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
